Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Cycle Pharmaceuticals Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00202293CT.gov Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Chlorpromazinum (this asset) | Cycle Pharmaceuticals Ltd. | Approved | BB · 66 |
| Asenapine | Dr. Stavroula Rakitzi | P4 | BBB |
| Citalopram | University of Texas Southwestern Medical Center | P4 | BBB |
| Paroxetine | Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | P4 | BBB |
| Quetiapine | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Escitalopram | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Lamotrigine | Johns Hopkins University | P4 | BBB |
| Lithium, Elemental | University of Aarhus | P4 | BBB |
| Sertraline | University of Texas Southwestern Medical Center | P4 | BBB |
+42 more in the Bipolar Disorder cohort
Other indications for Chlorpromazinum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophrenia | — | P4 | BB · 67 |
| Schizoaffective Disorder | — | P4 | BB · 65 |
| Glioblastoma | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AsenapineDr. Stavroula RakitziBBB
- CitalopramUniversity of Texas Southwestern Medical CenterBBB
- ParoxetineMental Health Centre Copenhagen, Bispebjerg and Frederiksberg HospitalBBB
- QuetiapineFirst Affiliated Hospital of Zhejiang UniversityBBB
- EscitalopramFirst Affiliated Hospital of Zhejiang UniversityBBB
Citation
Floatz Terminal. Chlorpromazinum in Bipolar Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/chlorpromazinum-bipolar-disorder-86461
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →